Screener
Relmada Therapeutics, Inc. RLMD Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055059
| Line item | As of / March 31, | As of |
|---|---|---|
| Accrued expenses | 7,160,233 | 4,861,583 |
| Total current liabilities | 12,891,634 | 6,430,527 |
| Stock appreciation rights | 3,738,583 | 1,060,931 |
| Total liabilities | 16,630,217 | 7,491,458 |
| Commitments and Contingencies (See Note 8) | ||
| Stockholders’ Equity: | ||
| Preferred stock, $0.001 par value, 200,000,000 shares authorized, none issued and outstanding | - | - |
| Class A convertible preferred stock, $0.001 par value, 3,500,000 shares authorized, none issued and outstanding | - | - |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Relmada Therapeutics, Inc.'s total liabilities?
- Relmada Therapeutics, Inc. (RLMD) reported total liabilities of $16.63M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s total liabilities changed year-over-year?
- Relmada Therapeutics, Inc.'s total liabilities increased by 217.4% year-over-year, from $5.24M to $16.63M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s total liabilities?
- Over 5 years (2020 to 2025), Relmada Therapeutics, Inc.'s total liabilities has grown at a -9.9% compound annual growth rate (CAGR), from $12.6M to $7.49M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Relmada Therapeutics, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude